Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

d clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. DelMar's scientific presentations can be viewed on the Company's website at www.delmarpharma.com.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 According ... Type (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, ... Manifold, & Rotary) & Geography - Global Trends ... and segments the lyophilization market on the basis ... and projections of the market size of each ...
(Date:9/19/2014)... , Sept. 19, 2014  Pressure BioSciences, Inc. ... it has received and approved all parts required ... and has begun to manufacture the new PCT-based ... will be ready for shipment by mid-October and ... released at a rate of about one per ...
(Date:9/19/2014)... N.Y. , Sept. 19, 2014  BioSpecifics Technologies Corp. ... in class collagenase-based products marketed as XIAFLEX ® in ... today that BioSpecifics, President, Tom Wegman , will present ... NewsMakers in the Biotech Industry Conference. The ... 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... ,GlaxoSmithKline (NYSE: GSK ; LSE) today announced ... granted Priority Review for PROMACTA(R),(eltrombopag) for the short-term ... PROMACTA is an investigational,once-daily oral treatment that induces ... generate platelets, which are critical in minimizing the,incidence ...
... 3 NicOx S.A.,(Euronext Paris: COX) today announced its ... activities during the year. NicOx also,announced today the initiation ... naproxcinod (see separate press release)., Key highlights ... phase 3 trials for naproxcinod ...
Cached Medicine Technology:FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 2FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 3FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 4Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 2Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 3Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 4Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 5Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 6Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 7Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 8Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 9Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 10Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 11Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 12Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 13Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 14Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs 15
(Date:9/19/2014)... (PRWEB) September 19, 2014 Top10BestSEOHosting.com ... and announces that HostMonster, Arvixe and Bluehost are ... to buy high quality WordPress hosting (including VPS ... their websites for more detailed information. , HostMonster ... get high-powered service at a fraction of the ...
(Date:9/19/2014)... Singulair, developed by Merck, is a CysLT1 ... (LTD4). LTD4 belongs to the family of Cys-LTs, which ... mast cells and eosinophils, and which bind to the ... there are higher concentrations of Cys-LTs in the airways ... production of CysLTs is increased in asthmatics, particularly during ...
(Date:9/19/2014)... York University researchers say a simple test that ... heightened risk for developing Alzheimer,s disease in a ... signs of dementia., Faculty of Health Professor Lauren ... the study asked the participants to complete four ... screen laptop computers. The test aimed at detecting ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... a traditional Scandinavian style of eating, is ... Much like Diet Doc’s medical weight ... cooking and eating good food which leads ... focuses on teaching patients to understand how ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... the 2014 NEXT Awards in the Technology Growth ... been selected as the sole female finalist for ... of Commerce and the Nashville Entrepreneur Center will ... of companies and individual entrepreneurs in five areas ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... Gardner HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay ... that sickened about 1,500 people and claimed two lives, U.S. ... identifying sources of food contamination and preventing further infection. ... an editorial accompanying the paper in the Feb. 23 online ...
... ways to enhance athletic performance have found that bovine ... as ,leaky gut syndrome., Their findings, published in ... Physiology-Gastrointestinal and Liver Physiology , could have positive implications ... heatstroke. A research group led by Ray Playford, ...
... T-cell receptor diversity in blood samples from healthy individuals has ... published online today in Genome Research ( www.genome.org ... disease, cancer, and immune system disorders. Adaptive immunity is ... attacks cells that may be infected with viruses or contain ...
... -- How quickly and smoothly people move on from a ... relationships each partner had in earliest childhood with the people ... from the the University of Minnesota,s ongoing tracking of a ... study participants were even born. Doctoral candidate Jessica E. ...
... High-resolution images from a laser-based tool developed at Duke ... of skin cancer, while potentially saving thousands of lives and ... The tool probes skin cells using two lasers to pump ... pointer, into a suspicious mole. Scientists analyze the way the ...
... Feb. 23 (HealthDay News) -- Smoking increases the production ... shows. U.S. researchers conducted tests on human airway ... smoke suppresses a protein that causes the natural death ... The study appears online ahead of print in ...
Cached Medicine News:Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 2Health News:Fast Response Crucial in Outbreaks of Food-Borne Illness: Study 3Health News:Is dairy colostrum the key to Olympic success? 2Health News:Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity 2Health News:Early Childhood Might Affect Love Life in Adult 2Health News:Lasers ID deadly skin cancer better than doctors 2Health News:Lasers ID deadly skin cancer better than doctors 3Health News:Cigarette Smoke Fuels Mucus Production in People With Bronchitis 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: